Fig. 3 | Scientific Reports

Fig. 3

From: Repurposing FDA-approved drugs and natural compounds to inhibit the RNA-dependent RNA polymerase domain of dengue virus 2 or dengue virus 3

Fig. 3

RdRp DENV-2 (a) RMSD values of chlortalidone-RdRp, clofazimine-RdRp, lumacaftor-RdRp, valdecoxib-RdRp, ZINC01532028-RdRp, ZINC01619649-RdRp, ZINC13378516-, ZINC14824819-RdRp, ZINC95913991 complexes, and unbonded RdRp. (b) Rg values of chlorthalidone-RdRp, clofazimine-RdRp, lumacaftor-RdRp, valdecoxib-RdRp, ZINC01532028-RdRp, ZINC01619649-RdRp, ZINC13378516, ZINC14824819-RdRp, ZINC95913991 complexes, and unbonded RdRp. (c) RMSF values of chlortalidone-RdRp, clofazimine-RdRp, lumacaftor-RdRp, valdecoxib-RdRp, ZINC01532028-RdRp, ZINC01619649-RdRp, ZINC13378516, ZINC14824819-RdRp, ZINC95913991 complexes, and unbonded RdRp. (d) H-bond values of the chlortalidone-RdRp, clofazimine-RdRp, lumacaftor-RdRp, valdecoxib-RdRp, ZINC01532028-RdRp, ZINC01619649-RdRp, ZINC13378516, ZINC14824819-RdRp, and ZINC95913991 complexes.

Back to article page